Daewoong Group Moves to Sell CG Bio to IMM PE
Transaction Estimated at Around 600 Billion Won
Daewoong Group announced on March 6 that it has selected IMM PE as the preferred bidder to acquire CG Bio, its affiliate in the regenerative medicine sector.
The stake up for sale is 51% of CG Bio, held by Aihana, a family company owned by the Daewoong Group owner's family and the largest shareholder of CG Bio.
The sale price and acquisition process will be finalized following due diligence and the signing of the main contract. Considering that the market values CG Bio at around 1 trillion won, there are projections that the deal could be made for approximately 600 billion won.
Hot Picks Today
"Two Spend 500,000 Won in a Flash, Yet Wait Two Hours?" ... 'Dreamland' Shunned by Kids and Foreign Tourists
- The Era of Getting 200 Million Won After 30 Years Is Over... A Japanese Bank's "Perpetual Department Head" Who Just Clocked In Cries Out
- Spain Hit by Its Worst Tragedy... Lee Kangin, Moreno and Real Madrid Join Soccer World in Mourning
- They Said, “Make It Your Home for Life” - Then Suddenly Kicked 200 Passengers Off... What Happened to the Around-the-World Cruise?
- "130 Rice Bowls Sold Out in a Day"... 'Unfiltered Face' Adds 8 Million Won to Night Market Sales: China's Bungeunwoo
CG Bio manufactures medical devices and therapeutics necessary for the regeneration of human tissues such as bone, skin, and blood vessels. The company posted sales of 200.8 billion won in 2024.
© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.